| Title |
Molecular profiling in the treatment of colorectal cancer: focus on regorafenib
|
|---|---|
| Published in |
OncoTargets and therapy, October 2015
|
| DOI | 10.2147/ott.s79145 |
| Pubmed ID | |
| Authors |
Yiyi Yan, Axel Grothey |
| Abstract |
Metastatic colorectal cancer (mCRC) is a highly heterogeneous disease. Its treatment outcome has been significantly improved over the last decade with the incorporation of biological targeted therapies, including anti-EGFR antibodies, cetuximab and panitumumab, and VEGF inhibitors, bevacizumab, ramucirumab, and aflibercept. The identification of predictive biomarkers has further improved the survival by accurately selecting patients who are most likely to benefit from these treatments, such as RAS mutation profiling for EGFR antibodies. Regorafenib is a multikinase inhibitor currently used as late line therapy for mCRC. The molecular and genetic markers associated with regorafenib treatment response are yet to be characterized. Here, we review currently available clinical evidence of mCRC molecular profiling, such as RAS, BRAF, and MMR testing, and its role in targeted therapies with special focus on regorafenib treatment. |
Mendeley readers
The data shown below were compiled from readership statistics for 58 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 2% |
| Portugal | 1 | 2% |
| Germany | 1 | 2% |
| Unknown | 55 | 95% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 13 | 22% |
| Student > Ph. D. Student | 9 | 16% |
| Student > Bachelor | 7 | 12% |
| Other | 5 | 9% |
| Student > Postgraduate | 5 | 9% |
| Other | 10 | 17% |
| Unknown | 9 | 16% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 18 | 31% |
| Biochemistry, Genetics and Molecular Biology | 13 | 22% |
| Agricultural and Biological Sciences | 8 | 14% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 5% |
| Immunology and Microbiology | 1 | 2% |
| Other | 3 | 5% |
| Unknown | 12 | 21% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 March 2021.
All research outputs
#8,343,963
of 25,584,565 outputs
Outputs from OncoTargets and therapy
#485
of 3,012 outputs
Outputs of similar age
#94,518
of 287,342 outputs
Outputs of similar age from OncoTargets and therapy
#10
of 102 outputs
Altmetric has tracked 25,584,565 research outputs across all sources so far. This one has received more attention than most of these and is in the 66th percentile.
So far Altmetric has tracked 3,012 research outputs from this source. They receive a mean Attention Score of 3.0. This one has done well, scoring higher than 80% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 287,342 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 66% of its contemporaries.
We're also able to compare this research output to 102 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 88% of its contemporaries.